Asset profile
CT-P17
Monoclonal antibody
Evidence outlook · results not reported
NCT03789292 · Rheumatoid Arthritis
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT03789292: The trial was a large randomized, quadruple-blind comparison of CT-P17 and Humira, with 324 participants per initial treatment group. Its primary clinical endpoint, ACR20 response at Week 24, had identical reported counts in both groups, but the registry does not state whether the prespecified statistical comparison met its criterion, so the result is unclear.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
76 competitors in this universe: 11 direct rivals (same mechanism and indication), 16 same-class, 49 same-indication; 37 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CT-P17: this drug | Phase 3 | Monoclonal antibody | TNF-alpha | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| CT-P13 (Inflectra / Remsima) | Approved | Monoclonal antibody | TNF-alpha | ||
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | ||
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | ||
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | ||
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | ||
| PF-06410293 | Approved | Monoclonal antibody | TNF-alpha | ||
| SAR441566 | Phase 2 | Small molecule | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha |
…and 61 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.